Research In Brief

AHRQ DES study: "Largest ever real-world study" comparing drug-eluting (DES) and bare metal stents (BMS) demonstrates the former were associated with significantly lower rates of death in Medicare patients undergoing percutaneous coronary intervention, Agency for Healthcare Research and Quality concludes in Feb. 10 research report. The study included 217,675 DES patients and 45,025 BMS patients. At 30 months, unadjusted rates of death were 12.9% for DES and 17.9% for BMS. Rates of myocardial infarction and revascularization were, respectively, 7.3 and 23.0 per 100 patients in the DES group, and 10.0 and 24.5 per 100 patients in the BMS arm. DES patients also had lower rates of adjusted death and MI, with minimal difference in revascularization, stroke or bleeding

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Archive

  • Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

    A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

  • Cardiac catheter reuse targeted by FDA; lab testing of used catheters planned.

    REUSE OF DISPOSABLE CARDIAC CATHETERS TARGETED BY FDA in an effort to address safety concerns about reuse of single-use products. The cardiac catheter product area "seems to jump up as one that is an area for us to focus on," Larry Spears, director of the Office of Compliance's Division of Enforcement III in FDA's Center for Devices and Radiological Health, said June 24 at a Food Drug and Law Institute conference held in Washington, D.C.

  • Heart valve sewing cuffs to be developed:

    St Jude Medical and Spire are to develop anti-bacterial heart valve sewing cuffs using Spire's Spi-Argent silver coating process. The agreement covers a variety of valve designs as well as ancillary components. The treatment is aimed at reducing the incidence of endocarditis, a rare but dangerous complication of valve transplant which has a mortality rate as high as 60%.

  • Nissho sales flat at only 1% in 1997:

    Nissho saw sales rise only 1% to ¥17 billion ($930 million) in the year to March 1997. The Japanese company's net income was Yen3 billion, compared with Yen1.7 billion for the previous year, reports Reuters. Nissho produces disposable medical equipment.

More from Medtech Insight